Myozyme for Pompe disease (glycogen storage disease type II)
Quick answer: Myozyme is used for Pompe disease (glycogen storage disease type II) as part of a enzyme replacement therapy (lysosomal) treatment regimen. Recombinant human alglucosidase alfa replaces deficient acid alpha-glucosidase to hydrolyze lysosomal glycogen The specific dosing for Pompe disease (glycogen storage disease type II) is determined by your prescriber based on individual factors.
Why is Myozyme used for Pompe disease (glycogen storage disease type II)?
Myozyme belongs to the Enzyme replacement therapy (lysosomal) class. Recombinant human alglucosidase alfa replaces deficient acid alpha-glucosidase to hydrolyze lysosomal glycogen This action makes it useful for treating or managing Pompe disease (glycogen storage disease type II) in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Myozyme is the right choice for a specific patient depends on the type and severity of Pompe disease (glycogen storage disease type II), response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Pompe disease (glycogen storage disease type II)
Common adult dosing range: 20 mg/kg IV every 2 weeks. The actual dose for Pompe disease (glycogen storage disease type II) depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Myozyme medicine page.
What to expect
Myozyme treatment for Pompe disease (glycogen storage disease type II) typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Pompe disease (glycogen storage disease type II)
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Myozyme is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Enzyme replacement therapy (lysosomal) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Myozyme
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Myozyme full prescribing information · All Enzyme replacement therapy (lysosomal) alternatives
Frequently asked questions
How effective is Myozyme for Pompe disease (glycogen storage disease type II)?
Effectiveness varies by individual response, dose, and severity. Myozyme is one of several treatment options for Pompe disease (glycogen storage disease type II), supported by clinical evidence within the enzyme replacement therapy (lysosomal) class. Discuss expected response with your prescriber.
How long do I need to take Myozyme for Pompe disease (glycogen storage disease type II)?
Treatment duration depends on the nature of Pompe disease (glycogen storage disease type II) — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Myozyme when used for Pompe disease (glycogen storage disease type II)?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Myozyme for Pompe disease (glycogen storage disease type II)?
Yes. Multiple medicines and non-drug options exist for Pompe disease (glycogen storage disease type II). Alternatives within the enzyme replacement therapy (lysosomal) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.